Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Exelixis

Drugmaker with rare disease work · based in Alameda, United States · founded 1994 · ticker EXEL · exelixis.com

Exelixis works on 5 rare diseases we track, including Familial Medullary Thyroid Carcinoma, Medullary Thyroid Cancer and 3 more. It has 5 active clinical trials, and 3 are looking for volunteers now. It also has 2 FDA-approved rare disease drugs.

Exelixis is an oncology-focused pharmaceutical company best known for cabozantinib, a multikinase inhibitor. It is sold as Cometriq for medullary thyroid cancer and as Cabometyx for kidney cancer, liver cancer and differentiated thyroid cancer, and since March 26, 2025 for previously treated, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults and children 12 and older.

Exelixis pipeline

Each row lists the diseases Exelixis is studying at that stage, from the ones closest to approval down to the earliest work.

Approved
Drugs the FDA has approved.
Phase 3
Large studies, usually the last step before a company asks the FDA for approval.
Phase 2
Mid-size studies that check whether a drug works and at what dose.

Non-Small Cell Lung Cancer recruiting · Neuroendocrine Tumors recruiting

Phase 1
First studies in people, mostly checking safety.
After approval
Studies that follow people already taking an approved drug.

Exelixis clinical trials

These are Exelixis trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.

3 trials looking for volunteers now

Looking for volunteersPhase 2Recently updatedNCT01639508

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Tests Cabozantinib

For Non-Small Cell Lung Cancer

The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment. RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits of RET, ROS1, NTRK, MET, and AXL. In addition, this drug interferes with other cell pathways that also cause cancer cells to grow, form new blood vessels, and spread to other organs of the body. The goal of using cabozantinib is to shrink the cancer and to prevent it from growing Cabozantinib has been studied and shown to cause cancer shrinkage in other cancers such as medullary thyroid cancer and prostate cancer. We thus have a good idea of what side-effects it causes and can anticipate them.

Ages 18 Years+7 locations
View full study
Looking for volunteersPhase 2/3Recently updatedNCT06943755

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Tests Zanzalintinib, Everolimus

For Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET)

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Ages 18 Years+135 locations
View full study
Looking for volunteersPhase 2Updated a few months agoNCT05263050

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Tests Cabozantinib, Nivolumab

For Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors and Carcinoid Tumor

This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.

Ages 18 Years+1 location
View full study

2 trials underway, not taking new volunteers

Underway, not taking new volunteersPhase 4Recently updatedNCT01896479

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Tests Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet, Placebo capsule

For Medullary Thyroid Cancer

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

Ages 18 Years+49 locations
View full study
Underway, not taking new volunteersPhase 1No updates in a whileNCT05249114

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Tests Cabozantinib, Lu-177

For Neuroendocrine Tumors

The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.

Ages 18 Years+1 location
View full study
Ask about Exelixis's trials
Answers with sources, in plain English
Start withor ask
Follow a condition Exelixis is studying

Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Exelixis. Unsubscribe anytime.

You'll get, for Familial Medullary Thyroid Carcinoma:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

FDA-approved drugs from Exelixis

From the openFDA database. Tap a drug for side effects, dosing and help paying.

Cabometyx cabozantinib

For Neuroendocrine Tumors. Approved Apr 25, 2016. Taken by mouth.

Cometriq cabozantinib

For Medullary Thyroid Cancer and Familial Medullary Thyroid Carcinoma. Approved Nov 29, 2012. Taken by mouth.

More about Exelixis

Its lead pipeline drug, zanzalintinib, is in the Phase 3 STELLAR-311 trial against everolimus in neuroendocrine tumors (NCT06943755). The rest of its pipeline, antibody-drug conjugates and other drugs in early trials, targets common solid tumors.

Where Exelixis trials take place

The trials above run at 193 study sites in 24 countries. Tap a country to see its states, cities and hospitals.

United States
50▼
France
18▼
Italy
18▼
Spain
17▼
Australia
10▼
United Kingdom
10▼
South Korea
8▼
Germany
7▼
Netherlands
7▼
Poland
7▼
Canada
5▼
Belgium
4▼

Rare diseases Exelixis works on

Each disease page lists every open trial, not only Exelixis's, plus approved treatments.

Familial Medullary Thyroid Carcinoma

Familial medullary thyroid carcinoma is an autosomal dominant cancer predisposition syndrome caused by germline RET mutations.

How common: Near-complete penetrance by adulthood in RET mutation carriers (varies by specific codon mutation); comprises ~25% of medullary thyroid cancers

Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor arising from the parafollicular C cells of the thyroid gland, accounting for 2-4% of all thyroid cancers.

How common: Approximately 1,000-1,200 new cases per year in the U.S.; 2-4% of all thyroid cancers

Neuroendocrine Tumors

Neuroendocrine tumors (NETs) grow from hormone-making cells, most often in the small intestine, pancreas, rectum or lungs.

How common: About 244,000 people in the US were living with a neuroendocrine neoplasm, the wider group that includes NETs, in 2021, with about 8.5 new diagnoses per 100,000 people a year (Dasari et al., JAMA Network Open 2025); an earlier estimate for NETs alone was about 171,000 in 2014 (JAMA Oncology 2017)

Paraganglioma

Paragangliomas are rare neuroendocrine tumors arising from chromaffin tissue outside the adrenal medulla.

How common: 1 in 300,000 to 1,000,000; ~30% are hereditary

Pheochromocytoma

Pheochromocytoma is a rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla that produces excessive catecholamines (epinephrine and norepinephrine).

How common: About 2 to 8 new cases per million people a year (National Cancer Institute)

Where to get support

Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Exelixis's own site is exelixis.com, and our help paying for treatment page lists drugmaker programs and charity funds.

Questions about Exelixis